S. Kennedy

ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized phase II trial.

R. Govindan, M. Ranson, N. Rizvi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preclinical Drug Testing of the CDK 4/6 Inhibitor Palbociclib in Combination With a PI3K or MEK Inhibitor in Colorectal Cancer Cell Lines

B. Hennessy, A. Farrelly, S. Madden, 2021 .

Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors

L. Grochow, E. Heath, M. Carducci, 2001, Cancer Chemotherapy and Pharmacology.

A phase II trial of PTK-787 (PTK/ZK) in recurrent or progressive meningiomas

J. Raizer, K. Muro, S. Grimm, 2008 .

A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours

D. Majumdar, C. Beattie, K. Christov, 2013, British Journal of Cancer.

Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer

P. Morris, A. Hill, B. Hennessy, 2018, Therapeutic advances in medical oncology.

Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer

A. Farrelly, S. Toomey, M. Cremona, 2023, Cancer biology & therapy.